Who Should Consider GLP-1 Therapy?

This week, Brent speaks with Dr. John Buse, a leading endocrinologist at the University of North Carolina and one of the world's foremost experts on diabetes and metabolic health. Dr. Buse unpacks the science behind GLP-1 agonists like Ozempic and Wegovy. He explains their powerful benefits for obesity, diabetes, and heart disease, along with the real risks. Drawing on his decades of research and personal experience using the drugs himself, Dr. Buse offers a grounded, evidence-based look at the promise and pitfalls of GLP-1s for both treatment and longevity. The conversation also touches on the future of microdosing, pharma ethics, and why true preventive care remains medicine's biggest challenge. He's a wonderful guest, hope you enjoy.